Nutrition
Volume 26, Issue 1 , Pages 33-39 , January 2010

Inhaled insulin—Intrapulmonary, intranasal, and other routes of administration: Mechanisms of action

  • R.I. Henkin, M.D., Ph.D.

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +202-364-4180; fax: +202-364-9727.

Received 17 April 2009 ,Accepted 3 August 2009.

References 

  1. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141–146
  2. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235–247
  3. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2:198–209
  4. Garcia-Contreras L, Smyth H. Liquid-spray or dry powder systems for inhaled delivery of peptide and proteins?. Am J Drug Deliv. 2005;3:29–45
  5. Onoue S, Hashimoto N, Yamada S. Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin Ther Pat. 2008;18:429–442
  6. Pfützner A, Mann AE, Steiner SS. Technosphere/Insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther. 2002;4:589–594
  7. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673–682
  8. Vanbever R, Ben-Jebria A, Mintzes JD, Langer R, Edwards DA. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res. 1999;48:178–185
  9. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng. 2002;4:93–107
  10. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143:549–558
  11. Gänsslen M. About inhalation of insulin. Klin Wochenschr. 1925;4:71
  12. Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. J Intern Med. 1996;240:93–98
  13. Laube BL, Benedict GW, Dobs AS. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest. 1998;114:1734–1739
  14. Rave KM, Heise T, Pfützner A, Steiner S, Heinemann L. Results of a dose-response study with a new insulin inhaler formulation. Diabetes. 2000;49:A75
  15. Barnett AH. Exubera inhaled insulin: a review. Int J Clin Pract. 2004;58:394–401
  16. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331–335
  17. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43:781–801
  18. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, et al. Dose–response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia. 2001;44:305–308
  19. Klonoff DC. Inhaled insulin. Diabetes Technol Ther. 1999;1:307–313
  20. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical consideration. Clin Pharmacokinet. 2008;47:595–610
  21. Katz IM, Schroeter JD, Martonen TB. Factors affecting the deposition of aerosolized insulin. Diabetes Technol Ther. 2001;3:387–397
  22. Newhouse MT. Tennis anyone? The lungs as a new court for systemic therapy. CMAJ. 1999;161:1287–1288
  23. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19:3–36
  24. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab. 2005;90:3287–3294
  25. Heinemann L, Traut T, Heise T. Time–action profile of inhaled insulin. Diabet Med. 1997;14:63–72
  26. Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J Aerosol Med. 1998;11:153–173
  27. Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother. 2005;39:843–853
  28. Jendle JH, Karlberg BE. Effects of intrapulmonary insulin in patients with non-insulin–dependent diabetes. Scand J Clin Lab Invest. 1996;56:555–561
  29. Hollander RA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356–2362
  30. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev. 2006;58:1061–1075
  31. Hirsch IB. Arguments against the use of inhaled insulin. Diabetes Technol Ther. 2007;9:S111–S114
  32. Waknine Y. Exubera gets lung cancer warning. Medscape Medical News, April 9, 2008. Available at: http://www.medscape.com. Accessed February 12, 2009.
  33. Schachner H. The science behind Exubera. Drug Dev Res. 2008;69:130–137
  34. Kling J. Inhaled insulin's last gasp?. Nat Biotechnol. 2008;26:479–480
  35. Henkin RI. Inhaled insulin for diabetes mellitus. N Engl J Med. 2007;356:2107
  36. Velicu I, Henkin RI. Insulin is present in human saliva and nasal mucus. J Invest Med. 2006;54:S385
  37. Velicu I, Henkin RI. Insulin receptors as well as insulin are present in saliva and nasal mucus. J Invest Med. 2006;54:S378
  38. Federico G, Maremmani C, Cinquanta L, Baroncelli GI, Fattori B, Saggese G. Mucus of the human olfactory epithelium contains the insulin-like growth factor-I system which is altered in some neurodegenerative diseases. Brain Res. 1999;835:306–314
  39. Henkin RI, Doherty AE, Martin BM. Nasal seroproteins: a new frontier in the exploration of physiology and pathology of nasal and sinus disease. In:  Veldman JE,  Passàli D,  Lim DJ editor. New frontiers in immunobiology in otolaryngology. The Hague: Kugler; 2000;p. 127–152
  40. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes. 1999;48:557–563
  41. Sigurdsson P, Thorvaldsson T, Gizurarson S, Gunnarsson E. Olfactory absorption of insulin to the brain. Drug Deliv. 1997;4:195–200
  42. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29:1326–1334
  43. Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27:451–458
  44. Hallschmid M, Benedict C, Schultes B, Perras B, Fehm HL, Kern W, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept. 2008;149:79–83
  45. Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH. Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001;187:91–97
  46. Liu XF, Fawcett JR, Thorne RG, Frey WH. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett. 2001;308:91–94
  47. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–496
  48. Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. Br Med J (Clin Res Ed). 1982;284:303–306
  49. Moses AC, Gordon GS, Carey MC, Flier JS. Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects. Diabetes. 1983;32:1040–1047
  50. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A, et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N Engl J Med. 1985;312:1078–1084
  51. Saffran M, Kumar G, Savariar C, Burnham J, Williams F, Neckers D. A new approach to the oral administration of insulin and other peptide drugs. Science. 1986;233:1081–1084
  52. Lassmann-Vaque V, Thiers D, Vialettes B, Vaque P. Preprandial intranasal insulin. Lancet. 1988;1:367–368
  53. Lalej-Bennis D, Boillot J, Bardin C, Zirinis P, Coste A, Escudier E, et al. Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. Diabetes Metab. 2001;27:372–377
  54. Dreyer K, Vaag A, Bech K, Hansen P, Sørensen AR, Mygind N. Intranasal administration of insulin with phospholipids as absorption enhancer: pharmacokinetics in normal subjects. Diabet Med. 1992;9:335–340
  55. Frauman AG, Cooper ME, Parsons BJ, Jerums G, Louis WJ. Long term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care. 1987;10:573–578
  56. Frauman AG, Jerums G, Louis WJ. Effects of intranasal insulin in non-obese type 2 diabetes. Diabetes Res Clin. 1987;3:197–202
  57. Hilsted J, Madsbad S, Hvidberg A, Rasmussen MH, Krarup T, Ipsen H, et al. Intranasal insulin therapy: the clinical realities. J Control Release. 1996;41:69–75
  58. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992;9:1–9
  59. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16:1576–1581
  60. Pillion DJ, Atchison JA, Gargiulo C, Wang RX, Wang P, Meezan E. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology. 1994;135:2386–2391
  61. Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 2003;87:187–198
  62. Benedict C, Dodt C, Hallschmid M, Lepiorz M, Fehm H, Born J, et al. Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. Metabolism. 2005;54:1356–1361
  63. Devere R. Are disease-modifying drugs for Alzheimer's already on the market?. Pract Neurol. 2008;7:14–15
  64. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early Alzheimer disease. Neurology. 2008;70:440–448
  65. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med. 2003;20:886–898
  66. Pozzilli P, Manfrini S, Costanza F, Coppolino G, Cavallo MG, Fioriti E, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism. 2005;54:930–934
  67. Aungst BJ, Rogers NJ, Shefter E. Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile sale absorption promoter. J Pharmacol Exp Ther. 1988;244:23–27
  68. Oh CK, Ritschel WA. Biopharmaceutic aspects of buccal absorption of insulin. Methods Find Exp Clin Pharmacol. 1990;12:205–212
  69. Heinemann L, Pfützner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des. 2001;7:1327–1351

PII: S0899-9007(09)00330-X

doi: 10.1016/j.nut.2009.08.001

Nutrition
Volume 26, Issue 1 , Pages 33-39 , January 2010

Article Tools